To include your compound in the COVID-19 Resource Center, submit it here.

miRagen reports systemic microRNA therapy data in CTCL

miRagen Therapeutics Inc. (NASDAQ:MGEN) reported interim data from the second part of an ongoing Phase I trial of MRG-106 in patients with mycosis fungoides-type cutaneous T cell lymphoma

Read the full 284 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE